This was demonstrated in both human and murine cell lines, including ruxolitinib-persistent BaF/3 cells which resistant up to 8μM ruxolitinib, and in JAK2-mutated ALL PDX samples cultured ex vivo. This evidence concerns the gene JAK2 and acute lymphoblastic leukemia.